Immunovant's IMVT-1402 600mg meets primary endpoint in difficult-to-treat rheumatoid arthritis trial

Immunovant's IMVT-1402 600mg met its primary endpoint in a difficult-to-treat rheumatoid arthritis trial, while the 300mg dose showed no difference from placebo. The company filed an 8-K with the SEC on the results.

Detected & updated continuously · Source: Nebula